Mervyn D I Vergouwen1, Amy V Jong-Tjien-Fa2, Ale Algra2, Gabriel J E Rinkel2. 1. From the Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (M.D.I.V., A.V.J.-T.-F., A.A., G.J.E.R.), and Julius Center for Health Sciences and Primary Care (A.A.), University Medical Center Utrecht, the Netherlands. M.D.I.Vergouwen@umcutrecht.nl. 2. From the Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (M.D.I.V., A.V.J.-T.-F., A.A., G.J.E.R.), and Julius Center for Health Sciences and Primary Care (A.A.), University Medical Center Utrecht, the Netherlands.
Abstract
OBJECTIVE: To compare causes of in-hospital death after aneurysmal subarachnoid hemorrhage (aSAH) in 2 time periods within the same institution. METHODS: From a prospectively collected institutional database, we retrieved data on 844 consecutive patients with aSAH admitted ≤3 days after ictus in 1999-2002 and 2009-2012. We assessed case-fatality <90 days and causes of in-hospital death and used Poisson regression analyses to calculate adjusted risk ratios (aRR) with corresponding 95% confidence intervals (CI) for change in individual causes of death, with the first time period as the reference group. RESULTS: Ninety-day case-fatality declined from 150/381 patients (39%) in 1999-2002 to 140/463 (30%) in 2009-2012 (aRR 0.74 [95% CI 0.62-0.88]). Compared with 1999-2002, the aRR for specific cause of in-hospital death in 2009-2012 was 1.06 (95% CI 0.72-1.56) for death from the initial bleeding, 0.47 (95% CI 0.31-0.71) for death from rebleeding, and 0.91 (95% CI 0.50-1.65) for death from delayed cerebral ischemia. Over time, the proportion of patients with in-hospital rebleeding declined from 90/381 (24%) to 78/463 (17%) (aRR 0.68 [95% CI 0.52-0.90]), median day of rebleeding from day 5 (IQR 1-10) to day 0 (IQR 0-1), and median day of aneurysm treatment from day 4 (IQR 2-13) to day 1 (IQR 1-2). CONCLUSIONS: An important contributor to the reduction in in-hospital death is the reduction in death from rebleeding, which probably results from earlier aneurysm treatment. Our results stress the need for early occlusion of the aneurysm and the need for other strategies that improve outcome by reducing the risk of rebleeding.
OBJECTIVE: To compare causes of in-hospital death after aneurysmal subarachnoid hemorrhage (aSAH) in 2 time periods within the same institution. METHODS: From a prospectively collected institutional database, we retrieved data on 844 consecutive patients with aSAH admitted ≤3 days after ictus in 1999-2002 and 2009-2012. We assessed case-fatality <90 days and causes of in-hospital death and used Poisson regression analyses to calculate adjusted risk ratios (aRR) with corresponding 95% confidence intervals (CI) for change in individual causes of death, with the first time period as the reference group. RESULTS: Ninety-day case-fatality declined from 150/381 patients (39%) in 1999-2002 to 140/463 (30%) in 2009-2012 (aRR 0.74 [95% CI 0.62-0.88]). Compared with 1999-2002, the aRR for specific cause of in-hospital death in 2009-2012 was 1.06 (95% CI 0.72-1.56) for death from the initial bleeding, 0.47 (95% CI 0.31-0.71) for death from rebleeding, and 0.91 (95% CI 0.50-1.65) for death from delayed cerebral ischemia. Over time, the proportion of patients with in-hospital rebleeding declined from 90/381 (24%) to 78/463 (17%) (aRR 0.68 [95% CI 0.52-0.90]), median day of rebleeding from day 5 (IQR 1-10) to day 0 (IQR 0-1), and median day of aneurysm treatment from day 4 (IQR 2-13) to day 1 (IQR 1-2). CONCLUSIONS: An important contributor to the reduction in in-hospital death is the reduction in death from rebleeding, which probably results from earlier aneurysm treatment. Our results stress the need for early occlusion of the aneurysm and the need for other strategies that improve outcome by reducing the risk of rebleeding.
Authors: M D I Vergouwen; D Backes; I C van der Schaaf; J Hendrikse; R Kleinloog; A Algra; G J E Rinkel Journal: AJNR Am J Neuroradiol Date: 2019-06-20 Impact factor: 3.825
Authors: Martin N Stienen; Johanna M Visser-Meily; Tom A Schweizer; Daniel Hänggi; R Loch Macdonald; Mervyn D I Vergouwen Journal: Neurocrit Care Date: 2019-06 Impact factor: 3.210
Authors: W E van der Steen; H A Marquering; L A Ramos; R van den Berg; B A Coert; A M M Boers; M D I Vergouwen; G J E Rinkel; B K Velthuis; Y B W E M Roos; C B L M Majoie; W P Vandertop; D Verbaan Journal: AJNR Am J Neuroradiol Date: 2020-05-14 Impact factor: 3.825
Authors: Airton Leonardo de Oliveira Manoel; Ann Mansur; Gisele Sampaio Silva; Menno R Germans; Blessing N R Jaja; Ekaterina Kouzmina; Thomas R Marotta; Simon Abrahamson; Tom A Schweizer; Julian Spears; R Loch Macdonald Journal: Neurocrit Care Date: 2016-12 Impact factor: 3.210
Authors: Reinier Wp Tack; Mervyn DI Vergouwen; Irene van der Schaaf; Albert van der Zwan; Gabriel Je Rinkel; Antti E Lindgren Journal: Eur Stroke J Date: 2019-02-01
Authors: Antti Lindgren; Mervyn DI Vergouwen; Irene van der Schaaf; Ale Algra; Marieke Wermer; Mike J Clarke; Gabriel Je Rinkel Journal: Cochrane Database Syst Rev Date: 2018-08-15
Authors: Sean N Neifert; Emily K Chapman; Michael L Martini; William H Shuman; Alexander J Schupper; Eric K Oermann; J Mocco; R Loch Macdonald Journal: Transl Stroke Res Date: 2020-10-19 Impact factor: 6.829